Tag: pharmaceutical

STOCKHOLM, June 22, 2026 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the company has entered into a research and...

— The study shows that EGFR-TKIs induce TROP2 upregulation in DTP cells, providing a mechanistic basis for combining sac-TMT with EGFR-TKI.— The Company is...

CAMBRIDGE, Mass., June 22, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and SK Biopharmaceuticals, a...

Drugmakers run the largest direct-to-consumer advertising category in the United States. New 5W research finds AI citation share does not follow the ad budget...

NOVATO, Calif., June 19, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 44,409 restricted stock units of the company’s common stock to 15 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of June 16, 2026, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).

SAN DIEGO and SEOUL, South Korea, June 19, 2026 /PRNewswire/ -- Seoul National University Hospital (SNUH) will take a major step toward expanding K-Bio's...

FLORHAM PARK, N.J., June 19, 2026 (GLOBE NEWSWIRE) -- Exeltis USA, Inc. (Exeltis), a global pharmaceutical company specializing in women’s health, announced that the U.S. Food and Drug Administration (FDA) has approved an update to the labeled strength of TWIRLA® (levonorgestrel and ethinyl estradiol) transdermal system. The new labeled strength will begin to appear on the market in September or October of 2026.

Lite Strategy to Attend Panel at Litecoin Foundation Summit in Amsterdam

Microsoft (MSFT) Faces Securities Fraud Class Action after Copilot Issues Cause 10% Stock Drop – Investors Notified to Contact BFA Law

Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma

DELRAY BEACH, Fla., June 19, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the gelatin market is estimated at USD 4.59 billion in 2026 and is...

TOKYO, June 19, 2026 /PRNewswire/ -- The NX Group, comprising companies under NIPPON EXPRESS HOLDINGS, Inc., will participate in "Multimodal 2026" to be held...

The Novo Nordisk Foundation is funding a new pan-European initiative to accelerate drug discovery for cardiometabolic diseases (CMDs).